[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

1490 Outcomes of Pregnancies for Women with Severe Chronic Neutropenia with or without G-CSF Treatment

Program: Oral and Poster Abstracts
Session: Granulocytes, Monocytes and Macrophages: Poster I
Saturday, December 4, 2010, 5:30 PM-7:30 PM
Hall A3/A4 (Orange County Convention Center)
Poster Board I-470

Laurence A. Boxer, MD1*, Audrey Anna Bolyard, RN, BS2*, Tracy M. Marrero3*, Blanche P Alter4, Mary Ann Bonilla, MD5*, Daniel Link, MD6, Peter E. Newburger, MD7, Philip S. Rosenberg8*, Akiko Shimamura, MD, PhD9 and David C. Dale, MD10

1University Of Michigan, Ann Arbor, MI
2Dept of Medicine, University of Washington, The Severe Chronic Neutropenia International Registry, Seattle, WA
3Dept Medicine, University of Washington, The Severe Chronic Neutropenia International Registry, Seattle, WA
4National Cancer Institute, Rockville
5Pediatric Hematology Oncology, St. Joseph's Children's Hospital, Paterson, NJ
6Division of Bone Marrow Transplantation, Washington University School of Medicine, St. Louis, MO
7Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA
8Division of Cancer Epidemiology and Genetics, NIH, National Cancer Institute, Rockville
9Pediatric Hem./Onc., Fred Hutchinson Cancer Research Center, Seattle, WA
10Dept of Medicine, University of Washington, Seattle, WA

There are currently no established guidelines for granulocyte colony stimulating factor (G-CSF) therapy during pregnancy for women with severe chronic neutropenia.  To establish treatment recommendations, we reviewed records of women with the diagnoses of congenital, cyclic, idiopathic or autoimmune neutropenia and blood neutrophil counts chronically or recurrently <0.5 x 109/L who were enrolled in the North American branch of the Severe Chronic Neutropenia International Registry (SCNIR). We identified 88 women who had 183 pregnancies for this cross sectional study. We compared outcomes for women treated or not treated with G-CSF during their pregnancies.

Fifty-five women [congenital neutropenia (CN) N=4, cyclic neutropenia (CyN) N=13, idiopathic neutropenia (IN) N=37, autoimmune neutropenia (AN) N=1] with 123 pregnancies while not on G-CSF therapy were compared with 41 women (CN =7, CyN=16, IN=15, AN=3) having 60 pregnancies while on G-CSF therapy.

During pregnancy the patients not treated with G-CSF had the following complications: 6 premature labors, 1 premature rupture of membranes, 2 life-threatening infections, and 2 minor infections. The G-CSF treated group had no premature labors, no life threatening infections, 5 minor infections, and 1 patient developed severe thrombocytopenia. By diagnostic category the complications in the no G-CSF mothers occurred in 11 patients (IN=9, CyN=1, AN=1), compared with six in the G-CSF treated group (IN=3, CyN=2, CN=1).  There were 32 spontaneous miscarriages in the women not on G-CSF (CN=1, CyN=8, and IN=23) compared with 3 in the women (CyN=3) on G-CSF.

There were 82 live births from 123 pregnancies in the no G-CSF group. Thirteen of these infants had neonatal neutropenia. Other major neonatal complications in this group included 3 significant infections (1 meningitis, 2 septicemias), 1 minor infection (umbilical cord infection), 1 cerebral palsy, 1 respiratory distress syndrome, and 1 collapsed lung. In the G-CSF treated group there were 53 live births from 60 pregnancies. Twelve of these infants were neutropenic. Other complications in the G-CSF treated group included 1 umbilical cord infection (in a patient of mother with congenital neutropenia) and 1 tracheal esophageal fistula, 1 abruptio placenta associated with neonatal apnea, and 1 hydronephrosis (in infants with cyclic neutropenic mothers).

The median G-CSF dose was 1.07 mcg/kg/day for all trimesters.  Treatment was administered throughout the pregnancy in 62% (37/60) of the pregnancies.  Seventeen percent (10/60) were treated only in the first trimester, 13% (8/60) were treated only in the last two trimesters, 3% (2/60) treated for the last trimester only, and 5% (3/60) treated in two of three trimesters (2 treated in 1st and 3rd trimesters, 1 treated in the 1st and 2nd trimesters).  The two live births with congenital abnormalities occurred in G-CSF treated patients; one with tracheal esophageal fistula was exposed in the first trimester, one with hydronephrosis was exposed in all three trimesters.

In summary, we found that G-CSF treatment was associated with a higher percentage of live births, 67% (82/123) without G-CSF compared with 88% (53/60) with G-CSF therapy (p=0.002, Fisher exact test).  G-CSF therapy was associated with a lower number of spontaneous abortions, 26% (32/123) in the no G-CSF group versus 5% (3/60) in the G-CSF treated group (p=0.001).  G-CSF therapy was associated with a lower rate of serious maternal complications. Two common congenital anomalies were observed in the offspring of the G-CSF treated mothers and no anomalies were observed in the offspring of the mothers not receiving G-CSF.  Overall the newborns from the G-CSF treated mothers appeared to have fewer neonatal complications.

Based on this analysis, we recommend that G-CSF therapy should be offered and continued during pregnancy in women with severe chronic neutropenia. The available data indicates that administration throughout pregnancy is well tolerated and protective of maternal health.

Disclosures: Boxer: Amgen, Inc.: Equity Ownership. Dale: Amgen: Consultancy, Research Funding.

*signifies non-member of ASH